Aminopeptidase inhibition as a targeted treatment strategy in myeloma

Myeloma cells are highly dependent on the unfolded protein response to assemble folded immunoglobulins correctly. Therefore, targeting protein handling within a myeloma cell by inhibiting the aminopeptidase enzyme system, which catalyses the hydrolysis of amino acids from the proteins NH2 terminus, represents a therapeutic approach. CHR-2797, a novel aminopeptidase inhibitor, is able to inhibit proliferation and induce growth arrest and apoptosis in myeloma cells, including cells resistant to conventional chemotherapeutics. It causes minimal inhibition of bone marrow stromal cell (BMSC) proliferation but is able to overcome the microenvironmental protective effects, inhibiting the proliferation of myeloma cells bound to BMSCs and the increase in vascular endothelial growth factor levels seen when myeloma cells and BMSCs are bound together. Additive and synergistic effects are seen with bortezomib, melphalan, and dexamethasone. Apoptosis occurs via both caspase-dependent and non-caspase-dependent pathways with an increase in Noxa, cleavage of Mcl-1, and activation of the unfolded protein response. Autophagy is also seen. CHR-2797 causes an up-regulation of genes involved in the proteasome/ubiquitin pathway, as well as aminopeptidases, and amino acid deprivation response genes. In conclusion, inhibiting protein turnover using the aminopeptidase inhibitor CHR-2797 results in myeloma cell apoptosis and represents a novel therapeutic approach that warrants further investigation in the clinical setting. [Mol Cancer Ther 2009;8(4):762–70]

[1]  Gary Box,et al.  CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. , 2008, Cancer research.

[2]  G. Morgan,et al.  A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma. , 2007 .

[3]  G. Morgan,et al.  Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. , 2007, Blood.

[4]  R. Bataille,et al.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.

[5]  M. L. Seibenhener,et al.  Sequestosome 1/p62 – More than just a scaffold , 2007, FEBS letters.

[6]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[7]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[8]  L. Boise,et al.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.

[9]  Kevin D. Nullmeyer,et al.  Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. , 2005, Cancer research.

[10]  P. Richardson,et al.  Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib , 2004, Cancer Research.

[11]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[12]  H. Kato,et al.  Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. , 2003, Journal of the National Cancer Institute.

[13]  G. Morgan,et al.  Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* , 2003, The Journal of Biological Chemistry.

[14]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[15]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Kilberg,et al.  Genomic sequences necessary for transcriptional activation by amino acid deprivation of mammalian cells. , 2002, The Journal of nutrition.

[17]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[18]  P. Richardson,et al.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications , 2001, Leukemia.

[19]  J. Lamb,et al.  Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells , 2000, British Journal of Cancer.

[20]  J. Lamb,et al.  Single Amino Acid (Arginine) Restriction: Growth and Death of Cultured HeLa and Human Diploid Fibroblasts , 2000, Cellular Physiology and Biochemistry.

[21]  K. Ota,et al.  Clinical trials of bestatin for leukemia and solid tumors , 1992, Biotherapy.

[22]  V. Botbol,et al.  Measurement of instant rates of protein degradation in the livers of intact mice by the accumulation of bestatin-induced peptides. , 1991, The Journal of biological chemistry.

[23]  F Sherman,et al.  The specificities of yeast methionine aminopeptidase and acetylation of amino-terminal methionine in vivo. Processing of altered iso-1-cytochromes c created by oligonucleotide transformation. , 1990, The Journal of biological chemistry.